国际口腔医学杂志

国际口腔医学杂志 ›› 2021, Vol. 48 ›› Issue (4): 459-467.doi: 10.7518/gjkq.2021061

• 综述 • 上一篇    下一篇

唾液腺导管癌的诊疗研究进展

马平川(),李春洁,李龙江()   

  1. 口腔疾病研究国家重点实验室 国家口腔疾病临床医学研究中心 四川大学华西口腔医院头颈肿瘤外科 成都 610041
  • 收稿日期:2020-11-20 修回日期:2021-04-12 出版日期:2021-07-01 发布日期:2021-06-30
  • 通讯作者: 李龙江
  • 作者简介:马平川,学士,Email： mapingchuan1997@126.com
  • 基金资助:
    国家自然科学基金(81870782);四川省卫生健康委员会科研课题(18PJ094)

Diagnosis and treatment of salivary duct carcinoma

Ma Pingchuan(),Li Chunjie,Li Longjiang()   

  1. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Dept. of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
  • Received:2020-11-20 Revised:2021-04-12 Online:2021-07-01 Published:2021-06-30
  • Contact: Longjiang Li
  • Supported by:
    National Natural Science Foundation of China(81870782);Scientific Research Project of Sichuan Provincial Health Commission(18PJ094)

RichHTML

34

PDF (PC)

595

摘要：

唾液腺导管癌（SDC）是发生于人体唾液腺的一种少见的侵袭性较强的上皮源性恶性肿瘤,最常发生于腮腺,常用的影像学检查方法包括超声、CT以及磁共振成像,也可以使用正电子发射型计算机断层显像判断肿瘤的位置以及远处转移,利用针吸细胞学检查也可以辅助诊断。SDC的治疗目前最常采用手术治疗加术后辅助放射和化学治疗,大多数患者同时接受颈部淋巴结清扫术,但术后辅助性放射和化学治疗的效果目前仍存在争议。对于SDC的靶向治疗是目前研究的热点,包括作用靶点为雄激素受体的雄激素阻断治疗以及作用于人表皮生长因子受体-2的以曲妥珠单抗为基础的治疗。SDC预后极差,但该疾病的不良预后因素还存在争议。本文就SDC的诊断、治疗以及预后相关研究进展作一综述,以促进该疾病的认识、诊断与治疗的发展。

关键词: 唾液腺导管癌, 诊断, 靶向治疗, 预后

Abstract:

Salivary duct carcinoma (SDC) is a rare and aggressive epithelial malignant tumor that occurs in human salivary glands, of which the parotid gland accounts for the largest proportion. The imaging examination of SDC includes ultrasound, CT, and magnetic resonance imaging. Positron emission tomography-computed tomography can also be used to determine tumor location and distant metastases. In addition, fine-needle aspiration cytology can be used in diagnosis. For the treatment of SDC, the most common method is surgery with postoperative adjuvant radiotherapy and chemotherapy. Moreover, most patients undergo neck dissection. However, the effects of postoperative adjuvant chemoradiotherapy remain unclear. At present, targeted therapies for SDC are considered as research hotspots, including androgen deprivation therapy targeting androgen receptor and Trastuzumab-based treatment targeting human epidermal growth factor receptor-2. Meanwhile, SDC has a poor prognosis. However, the determination of the adverse prognostic factors of the disease remains controversial. This article will review the research advances in the diagnosis, treatment, and prognosis of SDC to improve understanding of the diagnosis and treatment of this disease.

Key words: salivary duct carcinoma, diagnose, targeted therapy, prognosis

中图分类号: 

  • R781.7

表 1

近年SDC靶向治疗的文献回顾"

作用
位点		 参考文献 研究类型 患者数 用药方案 作用效果 预后
AR [28] 病例报告 8 比卡鲁胺50 mg·d-1+曲普瑞林每28 d注射3.6 mg 2名CR、2名PR、3名SD、1名PD 总体反应率：64.7%;5年生存率：19.3%;3年PFS：11.8%
AR [29] 病例报告 10 7名：比卡鲁胺150 mg·d-1;2名：比卡鲁胺50 mg·d-1;1名：比卡鲁胺50 mg·d-1+戈舍瑞林每4周3.6 mg 2名PR、3名SD、5名PD 中位PFS：12个月
AR [30] 回顾性
队列研究		 实验组：22;
对照组：111		 比卡鲁胺150 mg·d-1+戈舍瑞林每3月10.8 mg或曲普瑞林每28 d 3.25 mg 无 3年DFS：48.2%（95% CI：14.0%~82.4%）
3年OS：77.9%（95% CI：49.7%~100%）
AR [31] 回顾性
队列研究		 实验组：34;
对照组：43		 比卡鲁胺150 mg·d-1或比卡鲁胺50 mg·d-1+戈舍瑞林每4周3.6 mg 6名PR、11名SD、17名PD 中位OS：17个月（95% CI：10~24月）
中位PFS：4个月（95% CI：3~5月）
AR [32] 病例报告 1 比卡鲁胺80 mg·d-1+亮丙瑞林每4周3.75 mg 原发肿瘤与肺部转移肿瘤均增大 无
HER-2 [33] 病例报告 2 多西他赛每3周静脉给药75 mg·m-2+曲妥珠单抗每3周皮下注射600 mg+帕妥珠单抗每3周皮下注射420 mg,其中第1周期帕妥珠单抗加载剂量840 mg 2名PR 无
HER-2 [34] 病例报告 3 曲妥珠单抗每3周静滴6 mg·kg-1为1周期（第1周期为8 mg·kg-1）+紫杉醇每周80 mg·m-2 3名PR 无
HER-2 [35] 病例报告 1 紫杉醇175 mg·m-2+卡铂（6 AUC）+曲妥珠单抗（6 mg·kg-1）每21 d 1名SD 无
HER-2 [36] 病例报告 13 3名：仅使用曲妥珠单抗（每周4 mg·kg-1或2 mg·kg-1）;8名：曲妥珠单抗（每周4 mg·kg-1或2 mg·kg-1）+化学治疗;2名：曲妥珠单抗仅作为辅助治疗的一部分 3名SD、2名PR、4名无反应、1名PD、3名无法评估 无
HER-2 [37] 病例报告 2 曲妥珠单抗每周2 mg·kg-1（加载剂量4 mg·kg-1）+紫杉醇每周80 mg·m-2 1名PR、1名PD 无
HER-2 [38] 临床2期实验 57 曲妥珠单抗每3周静滴6 mg·kg-1为1周期（第1周期为8 mg·kg-1）+多西他赛每3周70 mg·m-2 总有效率70.2%（95% CI：56.6%~81.6%）;临床收益率84.2%（95% CI：72.1%~92.5%） 中位PFS：8.9个月（95% CI：7.8~9.9月）;中位OS：39.7个月
HER-2 [39] 病例报告 5 卡铂（5~6 AUC）+紫杉醇（175 mg·m-2）+曲妥珠单抗（2 mg·kg-1） 1名CR、2名PR、2名PD 中位PFS：18个月
[1] Gilbert MR, Sharma A, Schmitt NC, et al. A 20-year review of 75 cases of salivary duct carcinoma[J]. JAMA Otolaryngol Head Neck Surg, 2016,142(5):489-495.
doi: 10.1001/jamaoto.2015.3930 pmid: 26939990
[2] Kleinsasser O, Klein HJ, Hübner G. Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma[J]. Arch Klin Exp Ohren Nasen Kehlkopfheilkd, 1968,192(1):100-105.
pmid: 4301301
[3] Johnston ML, Huang SH, Waldron JN, et al. Salivary duct carcinoma: treatment, outcomes, and patterns of failure[J]. Head Neck, 2016,38(Suppl 1):E820-E826.
doi: 10.1002/hed.24107
[4] Breinholt H, Elhakim MT, Godballe C, et al. Salivary duct carcinoma: a Danish national study[J]. J Oral Pathol Med, 2016,45(9):664-671.
doi: 10.1111/jop.12426
[5] Otsuka K, Imanishi Y, Tada Y, et al. Clinical outcomes and prognostic factors for salivary duct carcinoma: a multi-institutional analysis of 141 patients[J]. Ann Surg Oncol, 2016,23(6):2038-2045.
doi: 10.1245/s10434-015-5082-2
[6] Osborn V, Givi B, Lee A, et al. Characterization, treatment and outcomes of salivary ductal carcinoma using the National Cancer Database[J]. Oral Oncol, 2017,71:41-46.
doi: 10.1016/j.oraloncology.2017.05.005
[7] Salovaara E, Hakala O, Bäck L, et al. Management and outcome of salivary duct carcinoma in major sa-livary glands[J]. Eur Arch Otorhinolaryngol, 2013,270(1):281-285.
doi: 10.1007/s00405-012-1997-4 pmid: 22437251
[8] Skálová A, Stenman G, Simpson RHW, et al. The role of molecular testing in the differential diagnosis of salivary gland carcinomas[J]. Am J Surg Pathol, 2018,42(2):e11-e27.
doi: 10.1097/PAS.0000000000000980
[9] Griffith CC, Seethala RR, Luvison A, et al. PIK3CA mutations and PTEN loss in salivary duct carcinomas[J]. Am J Surg Pathol, 2013,37(8):1201-1207.
doi: 10.1097/PAS.0b013e3182880d5a
[10] Qiu W, Tong GX, Turk AT, et al. Oncogenic PIK3CA mutation and dysregulation in human salivary duct carcinoma[J]. Biomed Res Int, 2014,2014:810487.
[11] Santana T, Pavel A, Martinek P, et al. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications[J]. Hum Pathol, 2019,93:37-47.
doi: 10.1016/j.humpath.2019.08.009
[12] Dalin MG, Desrichard A, Katabi N, et al. Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer[J]. Clin Cancer Res, 2016,22(18):4623-4633.
doi: 10.1158/1078-0432.CCR-16-0637
[13] Heřman J, Sedláčková Z, Fürst T, et al. The role of ultrasound and shear-wave elastography in evaluation of cervical lymph nodes[J]. Biomed Res Int, 2019,2019:4318251.
doi: 10.1155/2019/4318251 pmid: 31183367
[14] Celebi I, Mahmutoglu AS, Ucgul A, et al. Quantitative diffusion-weighted magnetic resonance imaging in the evaluation of parotid gland masses: a study with histopathological correlation[J]. Clin Imaging, 2013,37(2):232-238.
doi: 10.1016/j.clinimag.2012.04.025 pmid: 23465973
[15] Kim JY, Lee SW, Kim JS, et al. Diagnostic value of neck node status using 18F-FDG PET for salivary duct carcinoma of the major salivary glands[J]. J Nucl Med, 2012,53(6):881-886.
doi: 10.2967/jnumed.111.098384
[16] Lee SH, Roh JL, Kim JS, et al. Detection of distant metastasis and prognostic prediction of recurrent sa-livary gland carcinomas using 18 F-FDG PET/CT[J]. Oral Dis, 2018,24(6):940-947.
doi: 10.1111/odi.12877
[17] Eytan DF, Yin LX, Maleki Z, et al. Utility of preo-perative fine needle aspiration in parotid lesions[J]. Laryngoscope, 2018,128(2):398-402.
doi: 10.1002/lary.v128.2
[18] Lombardi D, McGurk M, Vander Poorten V, et al. Surgical treatment of salivary malignant tumors[J]. Oral Oncol, 2017,65:102-113.
doi: 10.1016/j.oraloncology.2016.12.007
[19] Cracchiolo JR, Shaha AR. Parotidectomy for paro-tid cancer[J]. Otolaryngol Clin North Am, 2016,49(2):415-424.
doi: 10.1016/j.otc.2015.10.007
[20] Olsen KD, Moore EJ. Deep lobe parotidectomy: cli-nical rationale in the management of primary and me-tastatic cancer[J]. Eur Arch Otorhinolaryngol, 2014,271(5):1181-1185.
doi: 10.1007/s00405-013-2616-8
[21] Park W, Park J, Park SI, et al. Clinical outcomes and management of facial nerve in patients with parotid gland cancer and pretreatment facial weakness[J]. O-ral Oncol, 2019,89:144-149.
[22] Deschler DG, Eisele DW. Surgery for primary malignant parotid neoplasms[J]. Adv Otorhinolaryngol, 2016,78:83-94.
[23] Huang X, Hao J, Chen S, et al. Salivary duct carcinoma: a clinopathological report of 11 cases[J]. Oncol Lett, 2015,10(1):337-341.
doi: 10.3892/ol.2015.3176
[24] Xiao CC, Zhan KY, White-Gilbertson SJ, et al. Predictors of nodal metastasis in parotid malignancies: a national cancer data base study of 22, 653 patients[J]. Otolaryngol Head Neck Surg, 2016, 154(1): 121-130.
[25] Jayaprakash V, Merzianu M, Warren GW, et al. Survival rates and prognostic factors for infiltrating salivary duct carcinoma: analysis of 228 cases from the Surveillance, Epidemiology, and End Results database[J]. Head Neck, 2014,36(5):694-701.
doi: 10.1002/hed.v36.5
[26] Kim TH, Kim MS, Choi SH, et al. Postoperative radiotherapy in salivary ductal carcinoma: a single institution experience[J]. Radiat Oncol J, 2014,32(3):125-131.
doi: 10.3857/roj.2014.32.3.125
[27] Qian K, Di L, Guo K, et al. Cervical lymph node metastatic status and adjuvant therapy predict the prognosis of salivary duct carcinoma[J]. J Oral Ma-xillofac Surg, 2018,76(7):1578-1586.
[28] Locati LD, Perrone F, Cortelazzi B, et al. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers[J]. Head Neck, 2016,38(5):724-731.
doi: 10.1002/hed.v38.5
[29] Jaspers HCJ, Verbist BM, Schoffelen R, et al. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options[J]. J Clin Oncol, 2011,29(16):e473-e476.
doi: 10.1200/JCO.2010.32.8351
[30] van Boxtel W, Locati LD, van Engen-van Grunsven ACH, et al. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma[J]. Eur J Cancer, 2019,110:62-70.
doi: 10.1016/j.ejca.2018.12.035
[31] Boon E, van Boxtel W, Buter J, et al. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in The Netherlands[J]. Head Neck, 2018,40(3):605-613.
doi: 10.1002/hed.v40.3
[32] Wasano K, Sakurai K, Kawasaki T, et al. Acquisition of resistance to androgen deprivation therapy in salivary duct carcinoma: a case report[J]. Rare Tumors, 2018,10:2036361318798867.
[33] van Boxtel W, Boon E, Weijs WLJ, et al. Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metasta-tic salivary duct carcinoma[J]. Oral Oncol, 2017,72:198-200.
doi: 10.1016/j.oraloncology.2017.06.023
[34] De Block K, Vander Poorten V, Dormaar T, et al. Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients[J]. Acta Clin Belg, 2016,71(6):383-388.
doi: 10.1080/17843286.2016.1173940
[35] Kaidar-Person O, Billan S, Kuten A. Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review[J]. Med Oncol, 2012,29(2):704-706.
doi: 10.1007/s12032-011-9884-1
[36] Perissinotti AJ, Lee Pierce M, Pace MB, et al. The role of trastuzumab in the management of salivary ductal carcinomas[J]. Anticancer Res, 2013,33(6):2587-2591.
[37] Gibo T, Sekiguchi N, Gomi D, et al. Targeted therapy with trastuzumab for epidermal growth factor receptor 2 (HER2)-positive advanced salivary duct carcinoma: a case report[J]. Mol Clin Oncol, 2019,11(2):111-115.
[38] Takahashi H, Tada Y, Saotome T, et al. Phase Ⅱ trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive sa-livary duct carcinoma[J]. J Clin Oncol, 2019,37(2):125-134.
doi: 10.1200/JCO.18.00545
[39] Limaye SA, Posner MR, Krane JF, et al. Trastuzu-mab for the treatment of salivary duct carcinoma[J]. Oncologist, 2013,18(3):294-300.
doi: 10.1634/theoncologist.2012-0369
[40] Xu B, Dogan S, Haroon Al, Rasheed MR, et al. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance[J]. Hum Pathol, 2019,93:30-36.
doi: 10.1016/j.humpath.2019.08.007
[41] Butler RT, Spector ME, Thomas D, et al. An immunohistochemical panel for reliable differentiation of salivary duct carcinoma and mucoepidermoid carcinoma[J]. Head Neck Pathol, 2014,8(2):133-140.
doi: 10.1007/s12105-013-0493-5
[42] Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer[J]. N Engl J Med, 2015,372(8):724-734.
doi: 10.1056/NEJMoa1413513
[43] Saintigny P, Mitani Y, Pytynia KB, et al. Frequent PTEN loss and differential HER2/PI3K signaling pa-thway alterations in salivary duct carcinoma: implications for targeted therapy[J]. Cancer, 2018,124(18):3693-3705.
doi: 10.1002/cncr.31600 pmid: 30289966
[44] Lin VTG, Nabell LM, Spencer SA, et al. First-line treatment of widely metastatic BRAF-mutated salivary duct carcinoma with combined BRAF and MEK inhibition[J]. J Natl Compr Canc Netw, 2018,16(10):1166-1170.
doi: 10.6004/jnccn.2018.7056
[45] Schmitt NC, Kang H, Sharma A. Salivary duct carcinoma: an aggressive salivary gland malignancy with opportunities for targeted therapy[J]. Oral Oncol, 2017,74:40-48.
doi: 10.1016/j.oraloncology.2017.09.008
[46] Mifsud M, Sharma S, Leon M, et al. Salivary duct carcinoma of the parotid: outcomes with a contemporary multidisciplinary treatment approach[J]. Otolaryngol Head Neck Surg, 2016,154(6):1041-1046.
doi: 10.1177/0194599816636812
[47] Villepelet A, Lefèvre M, Verillaud B, et al. Salivary duct carcinoma: prospective multicenter study of 61 cases of the Réseau d’Expertise Français des Cancers ORL Rares[J]. Head Neck, 2019,41(3):584-591.
doi: 10.1002/hed.v41.3
[48] Roh JL, Lee JI, Choi SH, et al. Prognostic factors and oncologic outcomes of 56 salivary duct carcinoma patients in a single institution: high rate of systemic failure warrants targeted therapy[J]. Oral Oncol, 2014,50(11):e64-e66.
doi: 10.1016/j.oraloncology.2014.08.010
[49] Shimura T, Tada Y, Hirai H, et al. Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas[J]. Oncotarget, 2018,9(2):1852-1867.
doi: 10.18632/oncotarget.v9i2
[50] Ryu HJ, Koh YW, Yoon SO. The implications of TrkA and MET aberrations in de novo salivary duct carcinoma[J]. Hum Pathol, 2018,81:18-25.
doi: 10.1016/j.humpath.2018.04.027
[1] 刘洋,尹德强. 关于颌位调整方法的思考和改进[J]. 国际口腔医学杂志, 2023, 50(5): 499-505.
[2] 李奕君, 徐子昂, 李一. 前哨淋巴结在头颈部鳞状细胞癌检测的应用进展[J]. 国际口腔医学杂志, 2023, 50(5): 521-527.
[3] 戢晓,张岚,黄定明. 牙源性与非牙源性上颌窦炎鉴别诊断及其治疗方案的研究进展[J]. 国际口腔医学杂志, 2023, 50(5): 566-572.
[4] 姜玥莹,何宇添,李婷,周蓉卉. 近红外荧光探针在口腔癌诊断中应用的研究进展[J]. 国际口腔医学杂志, 2023, 50(4): 407-413.
[5] 夏溦瑶,罗岩坤,贾仲林. Pierre Robin序列征的精准诊断和遗传病因学研究进展[J]. 国际口腔医学杂志, 2023, 50(3): 287-292.
[6] 李潭,梁新华. 盘状蛋白结构域受体1在调控恶性肿瘤进展和治疗中的作用[J]. 国际口腔医学杂志, 2023, 50(2): 230-236.
[7] 秦艺纯,谭学莲,黄定明. 腺牙源性囊肿的临床研究进展[J]. 国际口腔医学杂志, 2023, 50(1): 100-107.
[8] 李婷,杨学财,王俊伟. 儿童口腔颅颌面罕见畸形Williams-Beuren综合征的研究进展[J]. 国际口腔医学杂志, 2023, 50(1): 108-113.
[9] 李伟光,吴亚菲,郭淑娟. 无机纳米粒子在牙周病诊疗中的研究进展[J]. 国际口腔医学杂志, 2022, 49(6): 724-730.
[10] 朱星蓉,廖岚. 外胚叶发育不良综合征口腔临床诊疗的研究进展[J]. 国际口腔医学杂志, 2022, 49(6): 737-742.
[11] 曾杨林,谭学莲,宋东哲,黄定明. 牙根内吸收临床诊治方法的研究进展[J]. 国际口腔医学杂志, 2022, 49(5): 561-568.
[12] 叶泽林,刘璐,龙虎,游梦. 弯曲前牙的影像评价及治疗的研究进展[J]. 国际口腔医学杂志, 2022, 49(2): 173-181.
[13] 董栩,徐欣. 牙隐裂临床研究进展[J]. 国际口腔医学杂志, 2021, 48(6): 668-674.
[14] 白皓亮,杨禾,赵蕾. 牙周病风险评估及预后判断工具的研究进展[J]. 国际口腔医学杂志, 2021, 48(6): 696-702.
[15] 蒋宇磊,夏斌,饶南荃,杨禾丰,许彪. 外泌体在口腔鳞状细胞癌恶性进展及诊疗应用的研究[J]. 国际口腔医学杂志, 2021, 48(6): 711-717.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 张新春. 桩冠修复与无髓牙的保护[J]. 国际口腔医学杂志, 1999, 26(06): .
[2] 王昆润. 长期单侧鼻呼吸对头颅发育有不利影响[J]. 国际口腔医学杂志, 1999, 26(05): .
[3] 彭国光. 颈淋巴清扫术中颈交感神经干的解剖变异[J]. 国际口腔医学杂志, 1999, 26(05): .
[4] 杨凯. 淋巴化疗的药物运载系统及其应用现状[J]. 国际口腔医学杂志, 1999, 26(05): .
[5] 康非吾. 种植义齿下部结构生物力学研究进展[J]. 国际口腔医学杂志, 1999, 26(05): .
[6] 柴枫. 可摘局部义齿用Co-Cr合金的激光焊接[J]. 国际口腔医学杂志, 1999, 26(04): .
[7] 孟姝,吴亚菲,杨禾. 伴放线放线杆菌产生的细胞致死膨胀毒素及其与牙周病的关系[J]. 国际口腔医学杂志, 2005, 32(06): 458 -460 .
[8] 费晓露,丁一,徐屹. 牙周可疑致病菌对口腔黏膜上皮的粘附和侵入[J]. 国际口腔医学杂志, 2005, 32(06): 452 -454 .
[9] 赵兴福,黄晓晶. 变形链球菌蛋白组学研究进展[J]. 国际口腔医学杂志, 2008, 35(S1): .
[10] 庞莉苹,姚江武. 抛光和上釉对陶瓷表面粗糙度、挠曲强度及磨损性能的影响[J]. 国际口腔医学杂志, 2008, 35(S1): .